Canada markets closed

Bausch Health Companies Inc. (BHC)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
7.04-0.11 (-1.54%)
At close: 04:00PM EDT
7.17 +0.13 (+1.85%)
After hours: 07:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close7.15
Open6.97
Bid6.90 x 2200
Ask7.14 x 1300
Day's Range6.66 - 7.07
52 Week Range4.00 - 29.31
Volume7,455,107
Avg. Volume8,884,768
Market Cap2.566B
Beta (5Y Monthly)1.21
PE Ratio (TTM)50.29
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 10, 2010
1y Target EstN/A
  • CNW Group

    Bausch Health and Glenmark Announce the approval of RYALTRIS® in Canada

    Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) ("Bausch Health") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), are pleased to announce that RYALTRIS® (olopatadine hydrochloride and mometasone furoate nasal spray) has been approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.1

  • CNW Group

    Bausch Health Announces Early Exchange Offer Results for Exchange Offers and Consent Solicitations

    Bausch Health Companies Inc. (NYSE/TSX: BHC) (the "Company") announced today the results to date of its previously announced offers (the "Exchange Offers") to exchange the existing senior notes set forth in the table below (the "Existing Senior Notes") for up to an aggregate principal amount of $4.0 billion (subject to increase or decrease by the Offerors (as defined below), the "Maximum New Secured Notes Amount") of New Secured Notes (as defined below) and the related solicitations of consents

  • CNW Group

    Bausch Health Responds to Norwich Pharmaceuticals Tentative FDA Approval for a 200 mg Rifaximin

    Bausch Health Companies Inc. (NYSE/TSX: BHC) ("the Company"), and its gastroenterology business Salix Pharmaceuticals, today responded to the U.S. Food and Drug Administration's (FDA) tentative approval of the Norwich Pharmaceuticals rifaximin 200 mg product.